Department of Neurology Pitié-Salpêtrière Hospital, APHP-6, Sorbonne University, Paris, France.
Department of Neurology, FONDATION ADOLPHE DE Rothschild, Paris, France.
Mult Scler. 2021 Dec;27(14):2280-2283. doi: 10.1177/13524585211006372. Epub 2021 Apr 19.
Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses.
To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV.
Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS.
128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) ( = 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53-3.30, = 0.54).
These results suggest that YFV does not worsen the course of RR-MS.
黄热病疫苗（YFV）不建议多发性硬化症（MS）患者使用，因为疫苗接种后可能会有疾病复发的风险。
评估 YFV 接种后复发性缓解型多发性硬化症（RR-MS）恶化的风险。
这是一项非介入性观察性回顾性研究，在法国 MS 国家队列中嵌套了暴露/非暴露队列研究。
共纳入 128 例 RR-MS 患者。YFV 接种后 1 年的年复发率（ARR）在暴露组和非暴露组之间没有差异：暴露组为 0.219（0.420），非暴露组为 0.208（0.521）（ = 0.92）。两组之间首次复发的时间也没有差异（调整后的危险比（HR）= 1.33；95%置信区间（CI）= 0.53-3.30， = 0.54）。
这些结果表明 YFV 不会加重 RR-MS 的病程。
